The QuantRx Rapid-Sense lateral flow test is unique in that it is the only one-step positive-read lateral flow test on the market.

The advantages of RapidSense include the following:

• It can be incorporated into single-test or multiple-test platforms for drugs-of-abuse, HIV and other sexually transmitted diseases, as well as women’s health concerns such as pregnancy, fertility, ovulation, and menopause.
  
  
• The unique RapidSense lateral flow technology makes it ideal for testing both urine and oral fluids.
  
  
• Specific for qualitative or semi-quantitative detection of many analytes including antigens and antibodies.
  
  
• Capable of detecting analytes as small as 300 daltons including nutrients, hormones such as estrogen and progesterone, drugs-of-abuse, peptides and antibiotics, as well as small analytes of environmental and agricultural interest. However, it is not limited to small molecules and is equally applicable to molecular weights up to 250,000 daltons.
  
  
• While it can be designed as a positive-read or negative-read result, its greater precision and sensitivity render it the only one-step positive-read lateral flow test available.
  
  

RapidSense® Lateral Flow Test

Now in development is the QuantRx portfolio of drugs-of-abuse tests based on its RapidSense technology. In 2007 QuantRx plans to introduce 12 fully developed assays with corresponding Premarket Notification 510(k) filings with the U.S. Food and Drug Administration. Other products in development are oral fluid tests and a patented collection device for testing for drugs of abuse and communicable diseases including HIV and other sexually transmitted diseases.

In 2007 QuantRx expects to release several QuantRx-branded products as well as several QuantRx-developed OEM products for the point-of-care market for the professional as well as the over-the-counter market.